Organizational Overview:

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). Optimized as a subcutaneous injection with flexibility in dosing and approach, batoclimab is designed to reduce immunoglobin G (IgG) antibodies that cause inflammation and disease.

The Role:

Reporting directly to Chief Financial Officer, the Vice President of Investor Relations will lead the activities of all investor relations matters, including engagement with analysts and investors across multiple platforms, including corporate presentations, company website, investor events, non-deal roadshows, investor and analyst calls,press releases and earnings call scripts, and annual and quarterly SEC filings. The successful candidate will partner with the Chief Executive Officer and Chief Financial Officer to drive the company’s strategy, messaging and positioning, with a deep understanding of the broader industry trends and competitive landscape. The VP of Investor Relations will develop a deep understanding of the company’s clinical development milestones, market differentiation opportunities and key financial metrics. In addition to having established external relationships, the successful candidate  will own the day-to-day development and nurturing of existing and new investor and analyst relationships to support the company’s strategic objectives and investor community needs. The successful candidate  will evolve and lead an IR capability that thoughtfully, proactively, and credibly drives engagement with the investor community, provides insight and influence to the executive leadership team, and adds value to the overall business strategy.

This role will be able to clearly articulate the company’s positioning and differentiated approach and will balance near-term commitments and long-term options for driving value in creating the organization’s IR strategy. This role will collaborate cross-functionally internally with executive, clinical development and functional leaders. This leader will be expected to take a highly collaborative, iterative, and dynamic approach to the execution of the IR function. A flexible yet disciplined approach with scientific fluency and the ability to make connections to company-level strategy and external macro environment is critical. The successful candidate will need to bring investor and market-savvy expertise to the role in order to optimally position the company now and in the future. The VP of Investor Relations will have accountability for all investor relations deliverables including investor and analyst communications and content, and as needed for press releases, SEC filings, and board of director materials.

Key Responsibilities: 

  • Define and implement a strategic investor relations approach that clearly articulates Immunovant’s positioning and differentiation in the marketplace including the scientific attributes of batoclimab, competitive differentiation, clinical development roadmap, and financial plan.
  • Bring existing relationships and further develop Immunovant’s relationships with the analyst and shareholder community, driving appropriate interaction and communication with existing and potential investors elevating awareness and credibility of Immunovant’s story
  • Build analyst and investor intelligence and targeting strategies to increase the company’s positioning, awareness, and relevance externally with a goal to increase coverage by respected firms and further grow our high quality investor base.
  • Serve as the primary interface with buy- and sell-side analysts and investors, and drive the optimization of executive leaders’ role in market interactions increasing opportunities for high value exposure externally
  • Develop investor messaging/marketing communication in alignment with the business capital strategy, including relative to potential capital raises, business development opportunities, or other financing strategies.
  • Constantly gather intelligence on the marketplace, and inform, educate, and coach the company’s senior leadership regarding the investor and competitive landscape, providing insight on the potential impact of these market external forces on the company’s business opportunities.
  • Provide executive team and board members at the company with accurate and timely updates of the company’s positioning with analysts and key shareholders, as well as overall market trends in the biotech investor community.
  • Lead strategic communications development such as preparing presentation decks and creating management Q&A’s and conference call scripts. Additionally, provide insight on disclosure messaging and participate in the creation of the annual report and earnings releases.
  • Ensure consistency and alignment of the company’s messaging and participation at investor conferences and meetings, financial filings, and in internal communications.
  • Own and optimize relationships with external IR advisory services, use of external market and competitive intelligence tools, and vendors supporting IR content development and events.
  • Partner with CFO on the communications with and support of the Board of Directors as it relates to external communications and IR broadly.

Candidate Profile

The ideal candidate will be a strategic and proactive leader, with strong financial acumen and familiarity and comfort with clinical and scientific concepts. The ideal candidate will bring biotech/biopharma industry experience, including existing relationships and credibility with investors/analysts. The ideal candidate will establish the investor relations cadence and strategy for the business. The successful candidate will be a positive, roll-up-the-sleeves leader.

The VP of Investor Relations will have outstanding written and oral communication and interpersonal skills that will enable her or him to credibly serve as a primary representative for the company. This candidate will also be able to disagree, face confrontation, and introduce new concepts with tact, diplomacy, a sense of gravitas and executive presence that allow for productive and influential conversations.

The VP of Investor Relations will display an intellectual curiosity and horsepower that will enable the understanding of critical business drivers and the complexities of the evolving biotech landscape.  

Requirements:

  • Bachelor’s degree required; advanced finance degree desirable, advanced science degree strongly preferred
  • 10+ years of experience in biotechnology/pharmaceutical industry with a focus on investor relations, finance, equity research, and/or investment banking
  • Experience in having led public capital raises
  • Established relationships and credibility with the investment community
  • Ability to operate both at a deep level of detail and at the executive level
  • Ability to manage multiple tasks and competing priorities amid ambiguity and an ability to thrive working in a fast-paced, innovative environment
  • High intrinsic motivation and roll-up-the-sleeves mentality with the ability to work independently and to problem solve
  • A sense of accountability and an ability to anticipate and respond quickly to emerging information
  • Ability to digest and effectively communicate complex scientific and clinical data to the investment community
  • Ability to assess challenging dynamics, articulate options, and evaluate risks/benefits

 Work Environment:

  • Dynamic, interactive, fast-paced, and entrepreneurial environment
  • Immunovant’s headquarters is located in New York City. The position is flexible for partial remote work for a candidate with strong established industry / market networks in New York and/or Boston
  • Domestic travel required (up to 20%)

Apply for this Job

* Required
  
  


Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

As set forth in IMVT Corporation’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

Race & Ethnicity Definitions

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection. As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measure the effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categories is as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.


Form CC-305

OMB Control Number 1250-0005

Expires 05/31/2023

Voluntary Self-Identification of Disability

Why are you being asked to complete this form?

We are a federal contractor or subcontractor required by law to provide equal employment opportunity to qualified people with disabilities. We are also required to measure our progress toward having at least 7% of our workforce be individuals with disabilities. To do this, we must ask applicants and employees if they have a disability or have ever had a disability. Because a person may become disabled at any time, we ask all of our employees to update their information at least every five years.

Identifying yourself as an individual with a disability is voluntary, and we hope that you will choose to do so. Your answer will be maintained confidentially and not be seen by selecting officials or anyone else involved in making personnel decisions. Completing the form will not negatively impact you in any way, regardless of whether you have self-identified in the past. For more information about this form or the equal employment obligations of federal contractors under Section 503 of the Rehabilitation Act, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

How do you know if you have a disability?

You are considered to have a disability if you have a physical or mental impairment or medical condition that substantially limits a major life activity, or if you have a history or record of such an impairment or medical condition.

Disabilities include, but are not limited to:

  • Autism
  • Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, or HIV/AIDS
  • Blind or low vision
  • Cancer
  • Cardiovascular or heart disease
  • Celiac disease
  • Cerebral palsy
  • Deaf or hard of hearing
  • Depression or anxiety
  • Diabetes
  • Epilepsy
  • Gastrointestinal disorders, for example, Crohn's Disease, or irritable bowel syndrome
  • Intellectual disability
  • Missing limbs or partially missing limbs
  • Nervous system condition for example, migraine headaches, Parkinson’s disease, or Multiple sclerosis (MS)
  • Psychiatric condition, for example, bipolar disorder, schizophrenia, PTSD, or major depression

1Section 503 of the Rehabilitation Act of 1973, as amended. For more information about this form or the equal employment obligations of Federal contractors, visit the U.S. Department of Labor's Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.